Praneetha Panthagani

Praneetha Panthagani

Auto-generated profile, based on publicly available information

Praneetha Panthagani

Texas Tech University Health Sciences Center

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2024 in Alcoholism Treatment Quarterly
Verified
Journal Article
Open access
PPP. Panthagani
P. Panthagani
ASA. A. Shaik
A. A. Shaik
XLXiaobo Liu
Xiaobo Liu
SSS. Shanmugam
S. Shanmugam
BBB. Blough
B. Blough
SBS. E. Bergeson
S. E. Bergeson
Alcohol use disorder (AUD) poses a significant public health concern, with limited, high-efficacy, treatment options. Our lab has demonstrated that minocycline, an antibiotic with neuroprotective and immunomodulatory properties, is effective in reducing alcohol consumption in rodent models. We then synthesized antimicrobial-free minocycline derivatives to utilize their neuroprotective and immunomodulatory activities while mitigating antibiotic-related side effects. 10-Butyl Ether Minocycline (BEM) was chosen as a lead molecule based on efficacy and physicochemical properties from the library of compounds synthesized. Here, we report that BEM significantly reduced alcohol consumption in the Chronic Intermittent Ethanol (CIE) mouse model of alcohol dependence.

27 June 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
ASAbdul A. Shaik
Abdul A. Shaik
PPPraneetha Panthagani
Praneetha Panthagani
XLXiaobo Liu
Xiaobo Liu
SNStephany Navarro-Turk
Stephany Navarro-Turk
JGJeremy Garza
Jeremy Garza
SBSusan E. Bergeson
Susan E. Bergeson
The pleiotropy of minocycline (MINO), including anti-inflammatory, antioxidant, anti-migratory, anti-MMP, and neuroprotective effects, has been extensively reported. A novel non-antibiotic minocycline derivative, 10-butyl ether minocycline (BEM), was synthesized to retain the pleiotropy of minocycline while minimizing side effects such as antibiotic resistance and gut dysbiosis. Previously, we showed that BEM reduced alcohol consumption in dependent murine and porcine models of Alcohol Use Disorder (AUD). In this study, we investigated the molecular mechanisms of BEM to determine its potential as a therapeutic agent for neuroimmune and inflammatory conditions such as AUD. Here, we report that BEM showed a nearly complete loss of antimicrobial activity against E. coli , S. typhi, and C. albicans . BEM showed a dose-dependent reduction in cell viability as measured by the MTT assay, similarly to MINO. BEM also suppressed LPS-induced microglial activation as shown by reduced Iba1 expression in immunohistochemistry and western blot analyses. Inhibition of MMP-9 by BEM (IC50 = 42.2 µM) was improved compared to MINO (IC50 = 60.3 µM) while MMP-8 inhibition was moderate (IC50: BEM = 69.4 µM; MINO = 45.4 µM). BEM was found to be effective in inhibiting VEGF-induced endothelial cell migration and L-glutamine-induced ROS levels. Limited inhibition of 15-LOX activity was observed (IC50: BEM = 92.6 µM; MINO = 65.6 µM). BEM was not toxic to mitochondria, even at high concentrations (200 µM). By eliminating antimicrobial properties while preserving therapeutic pleiotropy, BEM presents an advancement in the development of a promising candidate with multimodal mechanisms to treat neuroimmune-inflammatory pathologies. Impact: Our current approach to correlate non-antibacterial actions of BEM to MINOs established mechanistic effects will enable the informed use of BEM for several medical indications including for inflammation and neuroimmune conditions. The focus on BEM’s multimodal actions and long-term safety during drug discovery represents a paradigm shift toward complex therapeutic drug development and repositioning, improving upon traditional singular high-affinity target-based approaches. Such new drug discovery attempts could potentially enhance treatment relevance in complex disorders with multiple targets and theoretically guide the creation of second-generation analogs. Significance statement: We report mechanisms of action for BEM, a minocycline analog under evaluation for the treatment of Alcohol Use Disorder, which may also show efficacy for other complex disease processes that involve inflammatory or neuroimmune components. We show that BEM had a nearly complete loss of antimicrobial action, yet retained the pleiotropy of MINO, likely making it a better multimodal therapeutic for long-term treatment of complex diseases with neuroimmune-related components. Visual

11 October 2025 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
ASAbdul Althaf Shaik
Abdul Althaf Shaik
PPPraneetha Panthagani
Praneetha Panthagani
XLXiaobo Liu
Xiaobo Liu
SNStephany Navarro
Stephany Navarro
JGJeremy Garza
Jeremy Garza
SBSusan E. Bergeson
Susan E. Bergeson

20 December 2025 in Alcoholism Treatment Quarterly
Verified
Journal Article
Closed access
PPPraneetha Panthagani
Praneetha Panthagani
ASAbdul Shaik
Abdul Shaik
XLXiaobo Liu
Xiaobo Liu
JSJordan Sanchez
Jordan Sanchez
MAMonica Aguilera
Monica Aguilera
SBSusan E Bergeson
Susan E Bergeson
Alcohol use disorder (AUD) is a complex brain disease with high morbidity, mortality, and limited treatment options, causing significant societal burden. Minocycline, well known for its anti-inflammatory and immunomodulatory properties, could potentially treat AUD but its antimicrobial activity would be inessential, and even a liability, for long-term treatment in AUD patients. 10-Butyl Ether Minocycline (BEM) was synthesized to retain minocycline’s off-target actions and eliminate antimicrobial properties. We hypothesized that BEM would reduce high ethanol consumption in common murine models of binge drinking without affecting ethanol elimination. The Drinking-In-the-Dark (DID) paradigm was used to assess BEM’s efficacy in reducing binge-like ethanol consumption. BEM dose-responsively reduced ethanol consumption in both female and male mice. Ethanol elimination following administration of both BEM and ethanol was evaluated using gas chromatography. BEM had no effect on ethanol metabolism in either sex, suggesting that its mechanism is independent and, thus, should not exacerbate ethanol-related toxicity when the two are taken together. Previous findings showed BEM effectively reduced chronic ethanol consumption. Future studies are underway to evaluate BEM’s potential as an AUD treatment, which so far have shown BEM to be safer than minocycline and inexpensive to produce.